Compare Walmart Stores Inc (WMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walmart Stores Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Walmart Stores Inc trades at $111.35 (market cap $877.15B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Walmart Stores Inc is far larger — about 86.8× State Street SPDR S&P Biotech ETF's market cap, and Walmart Stores Inc pays a 0.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walmart Stores Inc for 101 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WMT | XBI | |
|---|---|---|
Market Cap | $877.15B | $10.11B |
Volume | 23,616,578 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $134.20 | $169.55 |
52-Week Low | $100.61 | $104.99 |
Typical Hold Time | 101 Days | 38 Days |
Enterprise Value | $939.38B | — |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Walmart (WMT) trades at $110.56, up 2.27% with a bullish technical signal. The company demonstrates strong fundamentals with revenue reaching $680.99B in 2025 and consistent earnings beats. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships. The stock trades at a P/E of 40.06 and P/S of 1.2, reflecting premium valuation amid solid operational performance.
Walmart presents a compelling growth story with expanding digital services and market share gains. The primary investment opportunity lies in continued e-commerce momentum and operational efficiency. Key risks include valuation sensitivity, rising costs, and consumer spending pressures. Analyst consensus remains strongly bullish with a $128.84 price target, suggesting significant upside potential from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
